nodes	percent_of_prediction	percent_of_DWPC	metapath
Droxidopa—L-DOPA—Melphalan—ovarian cancer	0.878	1	CrCrCtD
Droxidopa—DDC—embryo—ovarian cancer	0.00339	0.0686	CbGeAlD
Droxidopa—Isoprenaline—MAPK1—ovarian cancer	0.0033	1	CrCbGaD
Droxidopa—ADRB3—female reproductive system—ovarian cancer	0.00282	0.057	CbGeAlD
Droxidopa—ADRB3—female gonad—ovarian cancer	0.00256	0.0519	CbGeAlD
Droxidopa—ADRA1D—epithelium—ovarian cancer	0.00213	0.0432	CbGeAlD
Droxidopa—Hyperpyrexia—Paclitaxel—ovarian cancer	0.00212	0.0853	CcSEcCtD
Droxidopa—DDC—female reproductive system—ovarian cancer	0.00206	0.0416	CbGeAlD
Droxidopa—SLC16A10—epithelium—ovarian cancer	0.0019	0.0384	CbGeAlD
Droxidopa—DDC—testis—ovarian cancer	0.00166	0.0336	CbGeAlD
Droxidopa—ADRA1D—female reproductive system—ovarian cancer	0.00159	0.0321	CbGeAlD
Droxidopa—SLC16A10—gonad—ovarian cancer	0.00158	0.0319	CbGeAlD
Droxidopa—ADRA2C—myometrium—ovarian cancer	0.00149	0.0301	CbGeAlD
Droxidopa—Myocardial ischaemia—Vinorelbine—ovarian cancer	0.00146	0.0588	CcSEcCtD
Droxidopa—SLC16A10—female reproductive system—ovarian cancer	0.00141	0.0285	CbGeAlD
Droxidopa—SLC16A10—vagina—ovarian cancer	0.00128	0.0258	CbGeAlD
Droxidopa—SLC6A2—decidua—ovarian cancer	0.00125	0.0252	CbGeAlD
Droxidopa—ADRA1A—epithelium—ovarian cancer	0.00123	0.0248	CbGeAlD
Droxidopa—DDC—lymph node—ovarian cancer	0.0012	0.0243	CbGeAlD
Droxidopa—ADRA2A—myometrium—ovarian cancer	0.00119	0.024	CbGeAlD
Droxidopa—ADRA2C—uterine cervix—ovarian cancer	0.00116	0.0234	CbGeAlD
Droxidopa—ADRB1—female reproductive system—ovarian cancer	0.00115	0.0233	CbGeAlD
Droxidopa—SLC16A10—testis—ovarian cancer	0.00114	0.023	CbGeAlD
Droxidopa—ADRA2C—decidua—ovarian cancer	0.0011	0.0223	CbGeAlD
Droxidopa—SLC6A2—gonad—ovarian cancer	0.0011	0.0222	CbGeAlD
Droxidopa—ADRA2C—endometrium—ovarian cancer	0.00105	0.0212	CbGeAlD
Droxidopa—Dizziness—Altretamine—ovarian cancer	0.00102	0.0412	CcSEcCtD
Droxidopa—Myocardial ischaemia—Paclitaxel—ovarian cancer	0.000983	0.0395	CcSEcCtD
Droxidopa—SLC6A2—female reproductive system—ovarian cancer	0.000979	0.0198	CbGeAlD
Droxidopa—ADRA2C—uterus—ovarian cancer	0.000965	0.0195	CbGeAlD
Droxidopa—ADRA2A—uterine cervix—ovarian cancer	0.000924	0.0187	CbGeAlD
Droxidopa—Nausea—Altretamine—ovarian cancer	0.00092	0.037	CcSEcCtD
Droxidopa—ADRA2A—decidua—ovarian cancer	0.00088	0.0178	CbGeAlD
Droxidopa—ADRA2A—endometrium—ovarian cancer	0.000836	0.0169	CbGeAlD
Droxidopa—Myocardial ischaemia—Docetaxel—ovarian cancer	0.000833	0.0335	CcSEcCtD
Droxidopa—SLC16A10—lymph node—ovarian cancer	0.000825	0.0167	CbGeAlD
Droxidopa—SLC6A2—testis—ovarian cancer	0.00079	0.016	CbGeAlD
Droxidopa—Blood pressure increased—Paclitaxel—ovarian cancer	0.00079	0.0318	CcSEcCtD
Droxidopa—ADRA2C—female gonad—ovarian cancer	0.000789	0.016	CbGeAlD
Droxidopa—ADRA2C—vagina—ovarian cancer	0.000785	0.0159	CbGeAlD
Droxidopa—ADRA2A—gonad—ovarian cancer	0.000775	0.0157	CbGeAlD
Droxidopa—ADRA2A—uterus—ovarian cancer	0.00077	0.0156	CbGeAlD
Droxidopa—ADRA2C—testis—ovarian cancer	0.0007	0.0142	CbGeAlD
Droxidopa—ADRA2A—female reproductive system—ovarian cancer	0.000692	0.014	CbGeAlD
Droxidopa—Blood pressure increased—Docetaxel—ovarian cancer	0.00067	0.0269	CcSEcCtD
Droxidopa—Cardiac failure congestive—Paclitaxel—ovarian cancer	0.000632	0.0254	CcSEcCtD
Droxidopa—ADRA2A—female gonad—ovarian cancer	0.00063	0.0127	CbGeAlD
Droxidopa—ADRA2A—vagina—ovarian cancer	0.000626	0.0127	CbGeAlD
Droxidopa—Arrhythmia—Melphalan—ovarian cancer	0.000603	0.0243	CcSEcCtD
Droxidopa—SLC6A2—lymph node—ovarian cancer	0.000573	0.0116	CbGeAlD
Droxidopa—ADRA2A—testis—ovarian cancer	0.000559	0.0113	CbGeAlD
Droxidopa—Confusional state—Chlorambucil—ovarian cancer	0.000555	0.0223	CcSEcCtD
Droxidopa—Cardiac failure congestive—Docetaxel—ovarian cancer	0.000536	0.0216	CcSEcCtD
Droxidopa—Arrhythmia—Vinorelbine—ovarian cancer	0.000527	0.0212	CcSEcCtD
Droxidopa—ADRA2C—lymph node—ovarian cancer	0.000507	0.0103	CbGeAlD
Droxidopa—Feeling abnormal—Chlorambucil—ovarian cancer	0.000454	0.0182	CcSEcCtD
Droxidopa—Hypertension—Vinorelbine—ovarian cancer	0.000443	0.0178	CcSEcCtD
Droxidopa—Urinary tract infection—Paclitaxel—ovarian cancer	0.00043	0.0173	CcSEcCtD
Droxidopa—ADRA2A—lymph node—ovarian cancer	0.000405	0.00819	CbGeAlD
Droxidopa—Feeling abnormal—Topotecan—ovarian cancer	0.000404	0.0162	CcSEcCtD
Droxidopa—Cardiac failure congestive—Epirubicin—ovarian cancer	0.000362	0.0145	CcSEcCtD
Droxidopa—Arrhythmia—Paclitaxel—ovarian cancer	0.000354	0.0143	CcSEcCtD
Droxidopa—Feeling abnormal—Vinorelbine—ovarian cancer	0.000345	0.0139	CcSEcCtD
Droxidopa—Cardiac failure congestive—Doxorubicin—ovarian cancer	0.000335	0.0135	CcSEcCtD
Droxidopa—Nausea—Chlorambucil—ovarian cancer	0.000327	0.0132	CcSEcCtD
Droxidopa—Dizziness—Topotecan—ovarian cancer	0.000324	0.013	CcSEcCtD
Droxidopa—Syncope—Paclitaxel—ovarian cancer	0.00031	0.0125	CcSEcCtD
Droxidopa—Headache—Topotecan—ovarian cancer	0.000307	0.0123	CcSEcCtD
Droxidopa—Loss of consciousness—Paclitaxel—ovarian cancer	0.000304	0.0122	CcSEcCtD
Droxidopa—Arrhythmia—Docetaxel—ovarian cancer	0.0003	0.0121	CcSEcCtD
Droxidopa—Hypertension—Paclitaxel—ovarian cancer	0.000298	0.012	CcSEcCtD
Droxidopa—Nausea—Topotecan—ovarian cancer	0.000291	0.0117	CcSEcCtD
Droxidopa—Nausea—Melphalan—ovarian cancer	0.000285	0.0115	CcSEcCtD
Droxidopa—Confusional state—Paclitaxel—ovarian cancer	0.000284	0.0114	CcSEcCtD
Droxidopa—Shock—Paclitaxel—ovarian cancer	0.000277	0.0112	CcSEcCtD
Droxidopa—Dizziness—Vinorelbine—ovarian cancer	0.000277	0.0111	CcSEcCtD
Droxidopa—Headache—Vinorelbine—ovarian cancer	0.000263	0.0106	CcSEcCtD
Droxidopa—Syncope—Docetaxel—ovarian cancer	0.000263	0.0106	CcSEcCtD
Droxidopa—Loss of consciousness—Docetaxel—ovarian cancer	0.000257	0.0104	CcSEcCtD
Droxidopa—Hypertension—Docetaxel—ovarian cancer	0.000253	0.0102	CcSEcCtD
Droxidopa—Nausea—Vinorelbine—ovarian cancer	0.000249	0.01	CcSEcCtD
Droxidopa—Urinary tract infection—Epirubicin—ovarian cancer	0.000246	0.00988	CcSEcCtD
Droxidopa—Confusional state—Docetaxel—ovarian cancer	0.000241	0.00969	CcSEcCtD
Droxidopa—Shock—Docetaxel—ovarian cancer	0.000235	0.00946	CcSEcCtD
Droxidopa—Feeling abnormal—Paclitaxel—ovarian cancer	0.000232	0.00934	CcSEcCtD
Droxidopa—Urinary tract infection—Doxorubicin—ovarian cancer	0.000227	0.00914	CcSEcCtD
Droxidopa—Arrhythmia—Epirubicin—ovarian cancer	0.000203	0.00815	CcSEcCtD
Droxidopa—Feeling abnormal—Docetaxel—ovarian cancer	0.000197	0.00792	CcSEcCtD
Droxidopa—Arrhythmia—Doxorubicin—ovarian cancer	0.000188	0.00754	CcSEcCtD
Droxidopa—Dizziness—Paclitaxel—ovarian cancer	0.000186	0.0075	CcSEcCtD
Droxidopa—Syncope—Epirubicin—ovarian cancer	0.000177	0.00712	CcSEcCtD
Droxidopa—Headache—Paclitaxel—ovarian cancer	0.000177	0.0071	CcSEcCtD
Droxidopa—Loss of consciousness—Epirubicin—ovarian cancer	0.000174	0.00698	CcSEcCtD
Droxidopa—Hypertension—Epirubicin—ovarian cancer	0.00017	0.00686	CcSEcCtD
Droxidopa—Nausea—Paclitaxel—ovarian cancer	0.000167	0.00674	CcSEcCtD
Droxidopa—Syncope—Doxorubicin—ovarian cancer	0.000164	0.00659	CcSEcCtD
Droxidopa—Confusional state—Epirubicin—ovarian cancer	0.000163	0.00654	CcSEcCtD
Droxidopa—Loss of consciousness—Doxorubicin—ovarian cancer	0.000161	0.00646	CcSEcCtD
Droxidopa—Shock—Epirubicin—ovarian cancer	0.000159	0.00638	CcSEcCtD
Droxidopa—Dizziness—Docetaxel—ovarian cancer	0.000158	0.00636	CcSEcCtD
Droxidopa—Hypertension—Doxorubicin—ovarian cancer	0.000158	0.00635	CcSEcCtD
Droxidopa—Confusional state—Doxorubicin—ovarian cancer	0.00015	0.00605	CcSEcCtD
Droxidopa—Headache—Docetaxel—ovarian cancer	0.00015	0.00602	CcSEcCtD
Droxidopa—Shock—Doxorubicin—ovarian cancer	0.000147	0.0059	CcSEcCtD
Droxidopa—Nausea—Docetaxel—ovarian cancer	0.000142	0.00571	CcSEcCtD
Droxidopa—Feeling abnormal—Epirubicin—ovarian cancer	0.000133	0.00534	CcSEcCtD
Droxidopa—Feeling abnormal—Doxorubicin—ovarian cancer	0.000123	0.00494	CcSEcCtD
Droxidopa—Dizziness—Epirubicin—ovarian cancer	0.000107	0.00429	CcSEcCtD
Droxidopa—Headache—Epirubicin—ovarian cancer	0.000101	0.00406	CcSEcCtD
Droxidopa—Dizziness—Doxorubicin—ovarian cancer	9.86e-05	0.00397	CcSEcCtD
Droxidopa—Nausea—Epirubicin—ovarian cancer	9.57e-05	0.00385	CcSEcCtD
Droxidopa—Headache—Doxorubicin—ovarian cancer	9.34e-05	0.00376	CcSEcCtD
Droxidopa—Nausea—Doxorubicin—ovarian cancer	8.86e-05	0.00356	CcSEcCtD
Droxidopa—ADRA2A—Signaling Pathways—IL6ST—ovarian cancer	7.63e-06	0.000174	CbGpPWpGaD
Droxidopa—ADRA1D—GPCR downstream signaling—AKT1—ovarian cancer	7.62e-06	0.000173	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—ERBB2—ovarian cancer	7.57e-06	0.000173	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling by GPCR—MAPK3—ovarian cancer	7.56e-06	0.000172	CbGpPWpGaD
Droxidopa—ADRB2—Signaling by GPCR—PIK3CA—ovarian cancer	7.54e-06	0.000172	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—CASP3—ovarian cancer	7.54e-06	0.000172	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—IL2—ovarian cancer	7.53e-06	0.000172	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—ERBB2—ovarian cancer	7.5e-06	0.000171	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling by GPCR—IL6—ovarian cancer	7.5e-06	0.000171	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—PIK3CB—ovarian cancer	7.47e-06	0.00017	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—MTOR—ovarian cancer	7.47e-06	0.00017	CbGpPWpGaD
Droxidopa—ADRB3—Signaling Pathways—TP53—ovarian cancer	7.43e-06	0.000169	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—ERBB2—ovarian cancer	7.41e-06	0.000169	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—PIK3CB—ovarian cancer	7.41e-06	0.000169	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—MTOR—ovarian cancer	7.41e-06	0.000169	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—CCND1—ovarian cancer	7.34e-06	0.000167	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—PIK3CG—ovarian cancer	7.33e-06	0.000167	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—APC—ovarian cancer	7.33e-06	0.000167	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling by GPCR—NRAS—ovarian cancer	7.33e-06	0.000167	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—MTOR—ovarian cancer	7.31e-06	0.000167	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—PIK3CB—ovarian cancer	7.31e-06	0.000167	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—CTNNB1—ovarian cancer	7.27e-06	0.000166	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling by GPCR—MAPK1—ovarian cancer	7.19e-06	0.000164	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling by GPCR—EGFR—ovarian cancer	7.19e-06	0.000164	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—CXCL8—ovarian cancer	7.18e-06	0.000164	CbGpPWpGaD
Droxidopa—ADRA2C—Metabolism—PTEN—ovarian cancer	7.15e-06	0.000163	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling by GPCR—PIK3CA—ovarian cancer	7.14e-06	0.000163	CbGpPWpGaD
Droxidopa—ADRB1—Signaling by GPCR—HRAS—ovarian cancer	7.14e-06	0.000163	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—MMP9—ovarian cancer	7.13e-06	0.000162	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—CXCL8—ovarian cancer	7.12e-06	0.000162	CbGpPWpGaD
Droxidopa—ADRB3—Signaling Pathways—HRAS—ovarian cancer	7.1e-06	0.000162	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—PTEN—ovarian cancer	7.09e-06	0.000161	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling by GPCR—HRAS—ovarian cancer	7.07e-06	0.000161	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—CXCL8—ovarian cancer	7.03e-06	0.00016	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling by GPCR—PIK3CA—ovarian cancer	7.03e-06	0.00016	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling by GPCR—MAPK3—ovarian cancer	7.02e-06	0.00016	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—CDKN1B—ovarian cancer	7.01e-06	0.00016	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—ERBB2—ovarian cancer	7.01e-06	0.00016	CbGpPWpGaD
Droxidopa—ADRB2—Signaling by GPCR—HRAS—ovarian cancer	6.98e-06	0.000159	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—CDKN1B—ovarian cancer	6.95e-06	0.000158	CbGpPWpGaD
Droxidopa—ADRB1—GPCR downstream signaling—AKT1—ovarian cancer	6.94e-06	0.000158	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—PIK3CD—ovarian cancer	6.94e-06	0.000158	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—PIK3CB—ovarian cancer	6.92e-06	0.000158	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—MTOR—ovarian cancer	6.92e-06	0.000158	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling by GPCR—AKT1—ovarian cancer	6.92e-06	0.000158	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—ERBB2—ovarian cancer	6.9e-06	0.000157	CbGpPWpGaD
Droxidopa—ADRA2B—GPCR downstream signaling—AKT1—ovarian cancer	6.88e-06	0.000157	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—CASP3—ovarian cancer	6.87e-06	0.000157	CbGpPWpGaD
Droxidopa—ADRA1A—GPCR downstream signaling—PIK3CA—ovarian cancer	6.87e-06	0.000157	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—IL2—ovarian cancer	6.86e-06	0.000156	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—CDKN1B—ovarian cancer	6.86e-06	0.000156	CbGpPWpGaD
Droxidopa—ADRB1—Signaling by GPCR—IL6—ovarian cancer	6.83e-06	0.000156	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—CASP3—ovarian cancer	6.81e-06	0.000155	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—PIK3CB—ovarian cancer	6.81e-06	0.000155	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—MTOR—ovarian cancer	6.81e-06	0.000155	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—IL2—ovarian cancer	6.8e-06	0.000155	CbGpPWpGaD
Droxidopa—ADRB3—Signaling Pathways—IL6—ovarian cancer	6.8e-06	0.000155	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling by GPCR—KRAS—ovarian cancer	6.79e-06	0.000155	CbGpPWpGaD
Droxidopa—ADRB2—GPCR downstream signaling—AKT1—ovarian cancer	6.79e-06	0.000155	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling by GPCR—IL6—ovarian cancer	6.77e-06	0.000154	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—CASP3—ovarian cancer	6.72e-06	0.000153	CbGpPWpGaD
Droxidopa—ADRA2A—Metabolism—PIK3CB—ovarian cancer	6.72e-06	0.000153	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—IL2—ovarian cancer	6.71e-06	0.000153	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—CCND1—ovarian cancer	6.69e-06	0.000152	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling by GPCR—MAPK1—ovarian cancer	6.68e-06	0.000152	CbGpPWpGaD
Droxidopa—ADRB2—Signaling by GPCR—IL6—ovarian cancer	6.68e-06	0.000152	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling by GPCR—EGFR—ovarian cancer	6.68e-06	0.000152	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—CXCL8—ovarian cancer	6.65e-06	0.000151	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—CCND1—ovarian cancer	6.63e-06	0.000151	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—CTNNB1—ovarian cancer	6.63e-06	0.000151	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling by GPCR—HRAS—ovarian cancer	6.6e-06	0.00015	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—CTNNB1—ovarian cancer	6.57e-06	0.00015	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—CCND1—ovarian cancer	6.55e-06	0.000149	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—CXCL8—ovarian cancer	6.54e-06	0.000149	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling by GPCR—HRAS—ovarian cancer	6.5e-06	0.000148	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—MMP9—ovarian cancer	6.5e-06	0.000148	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—CDKN1B—ovarian cancer	6.49e-06	0.000148	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—CTNNB1—ovarian cancer	6.48e-06	0.000148	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—PTEN—ovarian cancer	6.46e-06	0.000147	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—PIK3CD—ovarian cancer	6.45e-06	0.000147	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—MMP9—ovarian cancer	6.44e-06	0.000147	CbGpPWpGaD
Droxidopa—ADRA2C—GPCR downstream signaling—AKT1—ovarian cancer	6.42e-06	0.000146	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—VEGFA—ovarian cancer	6.4e-06	0.000146	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—PTEN—ovarian cancer	6.4e-06	0.000146	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—CDKN1B—ovarian cancer	6.39e-06	0.000146	CbGpPWpGaD
Droxidopa—ADRA2A—GPCR downstream signaling—PIK3CA—ovarian cancer	6.39e-06	0.000145	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—CASP3—ovarian cancer	6.36e-06	0.000145	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—MMP9—ovarian cancer	6.35e-06	0.000145	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—IL2—ovarian cancer	6.35e-06	0.000145	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—STAT3—ovarian cancer	6.34e-06	0.000144	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—NRAS—ovarian cancer	6.32e-06	0.000144	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling by GPCR—IL6—ovarian cancer	6.32e-06	0.000144	CbGpPWpGaD
Droxidopa—ADRA1B—GPCR downstream signaling—AKT1—ovarian cancer	6.32e-06	0.000144	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—PTEN—ovarian cancer	6.32e-06	0.000144	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling by GPCR—KRAS—ovarian cancer	6.31e-06	0.000144	CbGpPWpGaD
Droxidopa—ADRB1—Signaling by GPCR—AKT1—ovarian cancer	6.3e-06	0.000144	CbGpPWpGaD
Droxidopa—ADRB3—Signaling Pathways—AKT1—ovarian cancer	6.27e-06	0.000143	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—CASP3—ovarian cancer	6.26e-06	0.000143	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—IL2—ovarian cancer	6.25e-06	0.000142	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling by GPCR—AKT1—ovarian cancer	6.24e-06	0.000142	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling by GPCR—PIK3CA—ovarian cancer	6.24e-06	0.000142	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling by GPCR—IL6—ovarian cancer	6.22e-06	0.000142	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—CCND1—ovarian cancer	6.19e-06	0.000141	CbGpPWpGaD
Droxidopa—ADRB2—Signaling by GPCR—AKT1—ovarian cancer	6.16e-06	0.00014	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—CTNNB1—ovarian cancer	6.13e-06	0.00014	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—ERBB2—ovarian cancer	6.13e-06	0.00014	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—CCND1—ovarian cancer	6.1e-06	0.000139	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—MAPK3—ovarian cancer	6.06e-06	0.000138	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—PIK3CB—ovarian cancer	6.05e-06	0.000138	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—MTOR—ovarian cancer	6.05e-06	0.000138	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—CTNNB1—ovarian cancer	6.04e-06	0.000137	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—MMP9—ovarian cancer	6.01e-06	0.000137	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—PTEN—ovarian cancer	5.98e-06	0.000136	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—MMP9—ovarian cancer	5.92e-06	0.000135	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—MYC—ovarian cancer	5.89e-06	0.000134	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—PTEN—ovarian cancer	5.88e-06	0.000134	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—VEGFA—ovarian cancer	5.83e-06	0.000133	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling by GPCR—AKT1—ovarian cancer	5.83e-06	0.000133	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—CXCL8—ovarian cancer	5.81e-06	0.000132	CbGpPWpGaD
Droxidopa—ADRA2A—Metabolism—PTEN—ovarian cancer	5.81e-06	0.000132	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling by GPCR—PIK3CA—ovarian cancer	5.8e-06	0.000132	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—VEGFA—ovarian cancer	5.78e-06	0.000132	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—STAT3—ovarian cancer	5.78e-06	0.000132	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling by GPCR—HRAS—ovarian cancer	5.77e-06	0.000132	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—MAPK1—ovarian cancer	5.76e-06	0.000131	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—NRAS—ovarian cancer	5.76e-06	0.000131	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—EGFR—ovarian cancer	5.76e-06	0.000131	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling by GPCR—AKT1—ovarian cancer	5.74e-06	0.000131	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—STAT3—ovarian cancer	5.72e-06	0.00013	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—NRAS—ovarian cancer	5.71e-06	0.00013	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—VEGFA—ovarian cancer	5.71e-06	0.00013	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—ERBB2—ovarian cancer	5.69e-06	0.00013	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—CDKN1B—ovarian cancer	5.68e-06	0.000129	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—STAT3—ovarian cancer	5.65e-06	0.000129	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—NRAS—ovarian cancer	5.64e-06	0.000128	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—PIK3CB—ovarian cancer	5.62e-06	0.000128	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—MTOR—ovarian cancer	5.62e-06	0.000128	CbGpPWpGaD
Droxidopa—ADRA1A—GPCR downstream signaling—AKT1—ovarian cancer	5.61e-06	0.000128	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—CASP3—ovarian cancer	5.56e-06	0.000127	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—IL2—ovarian cancer	5.55e-06	0.000127	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling by GPCR—IL6—ovarian cancer	5.53e-06	0.000126	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—MAPK3—ovarian cancer	5.52e-06	0.000126	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—MAPK3—ovarian cancer	5.47e-06	0.000125	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—KRAS—ovarian cancer	5.44e-06	0.000124	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—CCND1—ovarian cancer	5.41e-06	0.000123	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—CXCL8—ovarian cancer	5.4e-06	0.000123	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—VEGFA—ovarian cancer	5.4e-06	0.000123	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—MAPK3—ovarian cancer	5.4e-06	0.000123	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—MYC—ovarian cancer	5.37e-06	0.000122	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling by GPCR—HRAS—ovarian cancer	5.36e-06	0.000122	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—CTNNB1—ovarian cancer	5.36e-06	0.000122	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—STAT3—ovarian cancer	5.35e-06	0.000122	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—NRAS—ovarian cancer	5.33e-06	0.000121	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—MYC—ovarian cancer	5.32e-06	0.000121	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—VEGFA—ovarian cancer	5.31e-06	0.000121	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—CDKN1B—ovarian cancer	5.27e-06	0.00012	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—STAT3—ovarian cancer	5.26e-06	0.00012	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—MMP9—ovarian cancer	5.26e-06	0.00012	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—MAPK1—ovarian cancer	5.25e-06	0.00012	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—MYC—ovarian cancer	5.25e-06	0.00012	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—EGFR—ovarian cancer	5.25e-06	0.00012	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—NRAS—ovarian cancer	5.25e-06	0.00012	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—PTEN—ovarian cancer	5.23e-06	0.000119	CbGpPWpGaD
Droxidopa—ADRA2A—GPCR downstream signaling—AKT1—ovarian cancer	5.22e-06	0.000119	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—MAPK1—ovarian cancer	5.2e-06	0.000119	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—EGFR—ovarian cancer	5.2e-06	0.000118	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—CASP3—ovarian cancer	5.17e-06	0.000118	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—IL2—ovarian cancer	5.16e-06	0.000118	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—MAPK1—ovarian cancer	5.14e-06	0.000117	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—EGFR—ovarian cancer	5.14e-06	0.000117	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling by GPCR—IL6—ovarian cancer	5.13e-06	0.000117	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—MAPK3—ovarian cancer	5.11e-06	0.000116	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling by GPCR—AKT1—ovarian cancer	5.1e-06	0.000116	CbGpPWpGaD
Droxidopa—ADRA2C—Metabolism—PIK3CA—ovarian cancer	5.04e-06	0.000115	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—CCND1—ovarian cancer	5.03e-06	0.000115	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—MAPK3—ovarian cancer	5.03e-06	0.000115	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—PIK3CA—ovarian cancer	5e-06	0.000114	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—CTNNB1—ovarian cancer	4.98e-06	0.000113	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—MYC—ovarian cancer	4.97e-06	0.000113	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—KRAS—ovarian cancer	4.96e-06	0.000113	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—KRAS—ovarian cancer	4.91e-06	0.000112	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—MYC—ovarian cancer	4.89e-06	0.000111	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—MMP9—ovarian cancer	4.88e-06	0.000111	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—MAPK1—ovarian cancer	4.86e-06	0.000111	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—EGFR—ovarian cancer	4.86e-06	0.000111	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—PTEN—ovarian cancer	4.86e-06	0.000111	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—KRAS—ovarian cancer	4.85e-06	0.000111	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—TP53—ovarian cancer	4.84e-06	0.00011	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—MAPK1—ovarian cancer	4.78e-06	0.000109	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—EGFR—ovarian cancer	4.78e-06	0.000109	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling by GPCR—AKT1—ovarian cancer	4.74e-06	0.000108	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—VEGFA—ovarian cancer	4.72e-06	0.000108	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—STAT3—ovarian cancer	4.67e-06	0.000106	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—NRAS—ovarian cancer	4.66e-06	0.000106	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—HRAS—ovarian cancer	4.63e-06	0.000105	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—KRAS—ovarian cancer	4.59e-06	0.000105	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—PIK3CA—ovarian cancer	4.56e-06	0.000104	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—KRAS—ovarian cancer	4.52e-06	0.000103	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—PIK3CA—ovarian cancer	4.51e-06	0.000103	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—MAPK3—ovarian cancer	4.47e-06	0.000102	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—PIK3CA—ovarian cancer	4.46e-06	0.000102	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—IL6—ovarian cancer	4.43e-06	0.000101	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—TP53—ovarian cancer	4.41e-06	0.0001	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—VEGFA—ovarian cancer	4.39e-06	9.99e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—TP53—ovarian cancer	4.37e-06	9.95e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—MYC—ovarian cancer	4.34e-06	9.89e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—STAT3—ovarian cancer	4.34e-06	9.89e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—NRAS—ovarian cancer	4.33e-06	9.87e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—TP53—ovarian cancer	4.31e-06	9.82e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—MAPK1—ovarian cancer	4.25e-06	9.68e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—EGFR—ovarian cancer	4.25e-06	9.68e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—PIK3CA—ovarian cancer	4.22e-06	9.61e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—HRAS—ovarian cancer	4.22e-06	9.6e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—HRAS—ovarian cancer	4.18e-06	9.51e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—PIK3CA—ovarian cancer	4.15e-06	9.45e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—MAPK3—ovarian cancer	4.15e-06	9.45e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—HRAS—ovarian cancer	4.12e-06	9.39e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Metabolism—AKT1—ovarian cancer	4.12e-06	9.38e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Metabolism—PIK3CA—ovarian cancer	4.1e-06	9.33e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—AKT1—ovarian cancer	4.09e-06	9.31e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—TP53—ovarian cancer	4.08e-06	9.29e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—MYC—ovarian cancer	4.04e-06	9.19e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—IL6—ovarian cancer	4.03e-06	9.19e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—TP53—ovarian cancer	4.02e-06	9.15e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—KRAS—ovarian cancer	4.01e-06	9.14e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—IL6—ovarian cancer	4e-06	9.11e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—MAPK1—ovarian cancer	3.95e-06	8.99e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—IL6—ovarian cancer	3.95e-06	8.99e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—EGFR—ovarian cancer	3.95e-06	8.99e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—HRAS—ovarian cancer	3.9e-06	8.89e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—HRAS—ovarian cancer	3.84e-06	8.75e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—IL6—ovarian cancer	3.73e-06	8.51e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—KRAS—ovarian cancer	3.73e-06	8.49e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—AKT1—ovarian cancer	3.72e-06	8.48e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—AKT1—ovarian cancer	3.69e-06	8.4e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—PIK3CA—ovarian cancer	3.69e-06	8.4e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—IL6—ovarian cancer	3.68e-06	8.37e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—AKT1—ovarian cancer	3.64e-06	8.29e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—TP53—ovarian cancer	3.57e-06	8.12e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—AKT1—ovarian cancer	3.45e-06	7.85e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—PIK3CA—ovarian cancer	3.43e-06	7.8e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—HRAS—ovarian cancer	3.41e-06	7.77e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—AKT1—ovarian cancer	3.39e-06	7.72e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Metabolism—AKT1—ovarian cancer	3.35e-06	7.62e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—TP53—ovarian cancer	3.31e-06	7.55e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—IL6—ovarian cancer	3.26e-06	7.44e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—HRAS—ovarian cancer	3.17e-06	7.22e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—IL6—ovarian cancer	3.03e-06	6.91e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—AKT1—ovarian cancer	3.01e-06	6.86e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—AKT1—ovarian cancer	2.8e-06	6.37e-05	CbGpPWpGaD
